Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21%

Highlights

• Telix Pharmaceuticals reported second-quarter revenue of US$247 million (A$353.2 million), up 21 per cent on the prior corresponding period, with precision-medicine sales rising 30 per cent to US$202 million.
• The company reaffirmed FY2026 group revenue guidance of US$950 million to US$970 million and says it is tracking toward the upper end of that range.
• Separately, it expects around US$40 million in non-refundable other income from Regeneron, taking total revenue and other income above US$1 billion. This US$40 million is NOT product revenue and sits on top of the sales guidance.
• Full-year research-and-development spending guidance was lifted to US$230 million to US$270 million, from a prior US$200 million to US$240 million, as late-stage clinical programs advance.
• The upgrade follows FDA alignment in early July 2026 to progress the ProstACT Global Phase 3 trial of prostate-cancer therapy candidate TLX591-Tx into its second part.

Telix Pharmaceuticals (ASX:TLX) said second-quarter revenue rose 21 per cent to US$247 million (A$353.2 million), led by a 30 per cent lift in precision-medicine sales to US$202 million. It reaffirmed FY2026 revenue guidance of US$950 million to US$970 million and is tracking toward the top of that range. Crucially, the company distinguishes product revenue from total "revenue and other income": adding about US$40 million of non-refundable income from its Regeneron collaboration pushes the combined figure above US$1 billion. That US$40 million is not sales. Telix also raised FY2026 R&D guidance to US$230 million to US$270 million to fund late-stage trials.

Telix Pharmaceuticals (ASX: TLX) has told the market it is on course to break through US$1 billion in combined revenue and other income this financial year, after a second quarter in which sales of its cancer-imaging products again outpaced expectations. The Melbourne-headquartered radiopharmaceuticals company, dual-listed on the Australian Securities Exchange and the Nasdaq, said quarterly revenue climbed 21 per cent to US$247 million (A$353.2 million), keeping it on track toward the upper end of full-year guidance.

The result underlines a pattern that has defined Telix's rise from a speculative biotech into one of the larger names in global nuclear medicine: a cash-generative diagnostic-imaging business that is bankrolling an ambitious and increasingly expensive move into radioligand cancer therapies. For investors, though, the headline figure comes with an important piece of accounting nuance that is worth reading carefully before drawing conclusions about the company's underlying trading.

The second-quarter result and upgraded outlook

For the three months to 30 June 2026, Telix reported group revenue of US$247 million, a 21 per cent increase on the prior corresponding period. The company attributed the growth to continued strength in its precision-medicine division, where revenue rose 30 per cent to US$202 million. Precision medicine houses Telix's commercial diagnostic-imaging agents, chief among them the prostate-cancer imaging product Illuccix, and is the engine that generates the bulk of group sales and cash flow.

On the back of that performance, Telix reaffirmed its FY2026 group revenue guidance of US$950 million to US$970 million and said it was tracking toward the upper end of the range. Telix reports on a calendar-year basis, so its 2026 financial year covers the 12 months to 31 December 2026; market coverage of the update referred to this period as 2025-26, but it corresponds to what the company labels FY2026. Achieving the top of guidance would represent revenue growth of roughly a fifth on the US$803.8 million the company booked in the 2025 financial year.

Reading the numbers: revenue versus 'revenue and other income'

The distinction that matters most in this announcement is the difference between revenue and total revenue and other income. These are not interchangeable, and conflating them overstates the underlying sales performance of the business.

The US$950 million to US$970 million guidance figure is revenue in the ordinary sense: money earned from selling products and services, overwhelmingly the imaging agents in the precision-medicine portfolio. Separately, Telix expects to recognise approximately US$40 million of non-refundable income arising from its strategic collaboration with the US biotechnology group Regeneron. That amount is not product revenue. It is other income tied to a partnership payment. When it is added to the sales guidance, the combined total, described by the company as revenue and other income, exceeds US$1 billion.

Put plainly: the more-than-US$1 billion milestone is a revenue-and-other-income figure, not a revenue figure. The US$40 million Regeneron component is a one-off style item rather than recurring trading income, and readers assessing the health of Telix's core commercial engine should anchor to the US$950 million to US$970 million range rather than the headline billion-dollar number.

The R&D guidance lift

Alongside the revenue commentary, Telix raised its FY2026 research-and-development spending guidance to a range of US$230 million to US$270 million, up from the US$200 million to US$240 million it flagged when it released full-year 2025 results in February. The increase, roughly US$30 million at both ends of the range, reflects a decision to accelerate late-stage clinical programs following recent regulatory progress on its prostate-cancer therapy candidate and the signing of the Regeneron collaboration.

Rising R&D is a double-edged signal. It demonstrates management's confidence that its therapeutic pipeline is worth backing harder, and that the commercial business can absorb the spend. But it also confirms that the path to a therapeutics franchise will keep pressure on the bottom line. Telix recorded a small loss before tax of US$5.3 million in FY2025, a swing from a US$38.0 million profit the year before, precisely because it chose to reinvest commercial gains into product development. A higher R&D envelope in FY2026 keeps that trade-off firmly in view.

How the quarter compares with the prior corresponding period

The 21 per cent revenue increase is measured against the second quarter of 2025, when Telix reported group revenue of approximately US$204 million, itself up 63 per cent year on year at the time. The deceleration in the growth rate, from the low-60s to the low-20s in percentage terms, is a natural consequence of a much larger revenue base rather than a sign of weakening demand; adding US$43 million of quarterly revenue on top of a US$204 million base is a materially bigger task than growing off earlier, smaller numbers.

Q2 2026 versus prior corresponding period (Q2 2025)

Precision-medicine revenue of US$202 million in the quarter implies a prior-period figure of roughly US$155 million, consistent with the continued ramp of Illuccix in the United States and the earlier commercial launch of the company's next-generation imaging agent, Gozellix. Investors should treat the implied pcp precision-medicine number as an approximation derived from the disclosed 30 per cent growth rate rather than a separately confirmed figure.

Inside Telix Pharmaceuticals (ASX: TLX) and its business model

Telix operates in radiopharmaceuticals, a field that pairs targeting molecules with radioactive isotopes to either image or treat disease. The company's commercial strategy rests on a deliberate sequencing: build a profitable diagnostic-imaging business first, then use the cash it throws off to fund the far more capital-intensive development of therapeutic products that use similar targeting biology to deliver radiation directly to tumours.

That model has proven durable. Group revenue reached US$803.8 million in FY2025, up 56 per cent on the US$516.6 million recorded in FY2024, with the precision-medicine segment carrying a gross margin around 64 per cent. The company closed 2025 with a cash balance of about US$141.9 million and has since bolstered its balance sheet through a US$550 million convertible-notes offering priced in April 2026, the proceeds of which are earmarked largely to refinance existing convertible debt due 2029, with the balance for general corporate purposes.

The commercial imaging portfolio

Telix's revenue is anchored by Illuccix, a PSMA-PET imaging agent used to help detect and stage prostate cancer, which remains the group's flagship product and the single largest contributor to sales. In March 2025 the US Food and Drug Administration approved Gozellix, a next-generation PSMA-PET prostate-imaging agent (developed as TLX007-CDx), broadening the company's prostate franchise. Beyond prostate cancer, Telix has been advancing a renal-cancer imaging candidate marketed as Zircaix (TLX250-CDx), which has been the subject of a biologics licence application before the FDA, and a brain-cancer imaging agent, Pixclara (based on TLX101), for which the FDA has accepted a new drug application covering glioma imaging. Together these products are intended to widen the diagnostic base that funds the therapeutics push, though the renal and brain-cancer assets remain subject to regulatory decisions and their commercial contribution is not yet established.

Industry and competitive context

Radiopharmaceuticals has become one of the more keenly contested corners of oncology, and Telix is far from alone. The therapeutic end of the market has been reshaped by Novartis, whose prostate-cancer radioligand therapy Pluvicto and companion imaging agent Locametz established that targeted radiation can be a commercial blockbuster. Eli Lilly moved into the space through its acquisition of Point Biopharma, while Bristol Myers Squibb bought RayzeBio, signalling that big pharma views radioligand therapy as a strategic priority rather than a niche.

On the diagnostic side, Telix's Illuccix competes most directly with Lantheus and its PSMA-PET imaging agent Pylarify (also known as PyL), a rivalry that has centred on the fast-growing US prostate-imaging market. The intensity of competition cuts both ways for Telix: it validates the clinical and commercial thesis behind precision radiopharmaceuticals, but it also means pricing, reimbursement and market share are perpetually contested, and that deep-pocketed competitors are racing to bring rival therapies to the same patient populations Telix is targeting with TLX591-Tx.

Growth drivers to watch

Several threads underpin Telix's ambition to keep scaling. The first is regulatory momentum in therapeutics. In early July 2026 the company announced it had achieved alignment with the FDA to advance its ProstACT Global Phase 3 trial of TLX591-Tx, a therapeutic candidate that combines the isotope lutetium-177 with the targeting molecule rosopatamab tetraxetan, into the trial's second part. The FDA confirmed that Part 1 safety data supported progression, and aligned with Telix on the Part 2 protocol, statistical analysis plan and safety-monitoring plan. TLX591-Tx is being studied in metastatic castration-resistant prostate cancer, and Part 2 is designed as a randomised expansion of roughly 490 patients combining the therapy with standard-of-care treatments. This is the regulatory progress management cited when lifting R&D guidance.

The second driver is the Regeneron collaboration announced in April 2026. Under that deal, Telix received a US$40 million upfront, non-refundable payment for access to its radiopharmaceutical manufacturing and supply-chain capabilities, paired with Regeneron's antibody-discovery expertise, to develop next-generation therapies against solid tumours. The partnership carries the potential for substantial additional milestone payments and cost-and-profit sharing over time, though those future amounts are contingent on development success and are separate from the US$40 million recognised this year. It is that upfront payment that lifts the group's FY2026 revenue-and-other-income figure above US$1 billion.

The third driver is capacity and portfolio breadth: continued Illuccix and Gozellix uptake, potential approvals and launches for the renal and brain-cancer imaging agents, and investment in the manufacturing and distribution network required to deliver short-half-life radioactive products reliably. Radiopharmaceuticals are logistically demanding because the isotopes decay quickly, so manufacturing footprint and supply-chain reliability are themselves competitive advantages.

Material risks and uncertainties

Against those drivers sit real risks that a balanced reading of the result should keep front of mind. Regulatory risk is the most obvious: pipeline assets such as Zircaix, Pixclara and TLX591-Tx depend on FDA and other regulators' decisions, which are inherently uncertain in timing and outcome. A late-stage clinical trial can miss its endpoints, and FDA alignment on a trial design is a procedural step, not a guarantee of eventual approval.

Competition and reimbursement pressure are structural. With Novartis, Lantheus, Lilly and Bristol Myers Squibb all active, Telix faces well-resourced rivals in both imaging and therapy, and its pricing and market share are exposed to payer decisions and evolving clinical guidelines. Concentration is another consideration: the business remains heavily weighted toward the United States and toward a small number of prostate-focused products, so a setback in either the US market or the prostate franchise would carry outsized consequences.

There is also the matter of R&D burn and profitability. Lifting development spending to as much as US$270 million while running only a slim margin of profit, or a small loss, means Telix is deliberately prioritising long-term pipeline value over near-term earnings. That is a defensible strategy, but it leaves less buffer if revenue growth slows. Finally, because Telix reports in US dollars while carrying an ASX listing and Australian cost base, currency movements can affect reported results, and its recent convertible-notes activity adds financing considerations that investors will want to track. None of these risks is unique to Telix, but collectively they temper the optimism embedded in the billion-dollar headline.

What ASX: TLX investors should monitor next

The most immediate signposts are regulatory. Decisions or updates on the renal-cancer imaging agent Zircaix and the glioma imaging agent Pixclara would materially shape the trajectory of the precision-medicine business, while the initiation and enrolment of Part 2 of the ProstACT Global trial will be the key marker for the therapeutics ambition. Beyond that, the full-year 2026 result, expected in early 2027, will show whether Telix landed at the upper end of guidance as management expects, and how the higher R&D spend flowed through to the bottom line and cash position.

Investors should also watch for further detail on the Regeneron collaboration, including any progression of the programs it covers, and for commentary on manufacturing capacity, given how central supply reliability is to this industry. Throughout, the cleanest way to gauge underlying momentum will be to separate reported product revenue from other income, and to read guidance ranges rather than single headline figures.

A balanced conclusion

Telix Pharmaceuticals (ASX: TLX) has delivered another quarter that validates its core proposition: a growing, high-margin imaging business capable of funding a serious tilt at cancer therapeutics. A 21 per cent revenue rise, guidance tracking toward the top of the range, and clear regulatory and commercial catalysts make for a genuinely constructive picture. The prospect of crossing US$1 billion in revenue and other income is a symbolic milestone for a company that only a few years ago was pre-revenue.

That milestone should nonetheless be read for what it is. The more-than-US$1 billion figure combines product revenue of US$950 million to US$970 million with roughly US$40 million of non-recurring Regeneron income; it is revenue and other income, not revenue alone. With R&D spending rising and the therapeutic pipeline still working through the clinic against formidable competitors, Telix's next chapter carries both meaningful upside and real execution risk. This article is general information only and does not constitute financial advice; it does not contain price forecasts or recommendations.